Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection

Drugs
G Jackson

Abstract

Erectile dysfunction (ED) is common in cardiac patients and shares the same risk factors--smoking, hypertension, hyperlipidaemia and diabetes mellitus. Sexual activity is not unduly stressful to the heart and, providing patients are properly assessed using established guidelines, sexual intercourse can be enjoyed without increased risk. The treatment of ED in patients with cardiovascular disease has been transformed by the introduction of the oral phosphodiesterase type 5 inhibitors, the first of which was sildenafil. Success in restoring erectile function is possible in up to 80% of patients (depending on the aetiology) with minimal adverse effects. A synergistic hypotensive effect with nitrates, and almost certainly nicorandil, is the only major contraindication. ED in asymptomatic patients may be a marker of silent vascular disease or increased vascular risk factors and should alert the physician to the need for cardiac risk screening. ED is common in patients with cardiovascular disease and should be routinely enquired about. ED is a distressing condition for the man and his partner, and severely impairs quality of life. Patients with cardiovascular disease and patients with diabetes represent the largest group of patients ...Continue Reading

References

Apr 15, 1995·The American Journal of Cardiology·Y DroryA Pines
Aug 1, 1993·Australian Family Physician·G S Reisner
Oct 7, 1997·International Journal of Impotence Research·A GreensteinZ Braf
May 6, 1998·International Journal of Andrology·A BortolottiM Landoni
Jun 22, 1999·JAMA : the Journal of the American Medical Association·C Marwick
Dec 14, 1999·Circulation·J T Willerson
Jun 1, 2000·The New England Journal of Medicine·H C HerrmannP D Mahoney
Jul 6, 2000·The New England Journal of Medicine·T D Coulter, H P Wiedemann
Apr 6, 2001·World Journal of Urology·J P Heaton
Oct 18, 2002·Journal of the American College of Cardiology·Julian P J HalcoxArshed A Quyyumi
Jan 11, 2003·The American Journal of Cardiology·Hemant SolomonGraham Jackson
Dec 9, 2003·European Heart Journal·Kim M FoxUNKNOWN CAESAR I (Clinical American and European Studies of Angina and Revascularization) investigators

❮ Previous
Next ❯

Citations

Jan 25, 2005·Current Diabetes Reports·Glenn MatfinVivian A Fonseca
Feb 17, 2007·Cardiology in Review·Gautham RavipatiWilliam H Frishman
Aug 19, 2010·Pharmacological Reviews·Sharron H FrancisDavid Sibley
Nov 6, 2015·Nitric Oxide : Biology and Chemistry·Riccardo LacchiniJose E Tanus-Santos
Aug 25, 2017·Current Cardiology Reports·Jay Pravin PatelCharles N Walker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.